The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues.
about
Roles and relevance of mast cells in infection and vaccinationHelicobacter pylori vaccination: is there a path to protection?Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.Influenza A viruses: why focusing on M2e-based universal vaccines.Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparumIntranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathologySubcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.Vaccine Potentiation by Combination AdjuvantsAdherence-inhibitory intestinal immunoglobulin a antibody response in baboons elicited by use of a synthetic intranasal lectin-based amebiasis subunit vaccine.ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.Immunologic uniqueness of the genital tract: challenge for vaccine development.Intranasal delivery of vaccines against HIV.Delivery systems and adjuvants for oral vaccines.Strategies for optimizing targeting and delivery of mucosal HIV vaccines.The ABC of clinical and experimental adjuvants--a brief overview.Mechanisms of Cholera Toxin in the Modulation of TH17 Responses.Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins.Intranasal delivery of nanoparticle-based vaccines.Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice.Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis.The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections
P2860
Q26777264-1A660B18-0E10-4B06-A6AD-F9C417C1BEF7Q26865279-95F4EC57-D9E0-4482-BDF4-26F482AE6C28Q30375991-AAA595EC-8CD0-4114-B605-DE64C509318CQ30396318-1CA10DA7-092F-4854-8168-5C1716C3E369Q34111897-86BE5883-7AC1-4A64-A3D2-A529656A70F3Q34309830-775F29D2-7EA9-436A-B2F7-2EB4DEE2269CQ34685461-F9990BEF-0016-4F37-9C7F-8109413F8EBBQ35082439-721226F3-C9F2-4BA7-9AD5-A4ECD744526CQ35142923-7575CF26-A913-4A0B-B517-409B068CD9C7Q35689134-33C60F97-D6B7-4C55-BB76-6125ACFD6EC7Q35747402-7A9991A1-30AB-458C-BC94-476651B8F36EQ35826767-19806A9A-C0E6-4BB4-96F4-D8829FDAF6C9Q35949888-C1B9F1EF-D371-4644-BCDA-99C9FE0DFE91Q36024836-B9128077-491F-4C9D-A918-87C5DF375B5BQ36099546-827D4E76-0ED8-464D-B8C1-FC0874D08F2DQ36409054-FDB1ADB2-6ED9-46FB-BA18-629E13F33619Q36640326-C3C177A0-4A5F-4487-92DE-6C7F3F02158BQ37554135-11BE5DE8-0EFC-4104-B338-1386D39E0423Q37628867-D654A737-CF7A-4777-9E66-6CCE15F3820CQ37641941-BF911F7F-60DE-4A3A-95EE-1257D38365D8Q37789144-D57AE80E-2576-40D9-9BE9-5D7E6D3E6EBEQ39113247-8FFD72E2-F40B-4785-B21D-F610117640DDQ39384289-18FB5F04-9FE7-4932-87B6-A06B10F8E767Q40228221-EFD79ED6-8DDD-4AE3-B085-F4B6DEB137A2Q42723998-2D1460B8-3C39-46F4-AAD5-1CF3F2E81473Q43170567-5A264560-7F9B-43C5-A966-15F48C1D0E84Q45990900-DCEA9AAF-DB95-48DD-95C5-94D917A44726Q46942390-F9DE2971-C238-4720-B381-566F3BEB9573Q52715734-4215FD8C-7289-4987-B8BE-E23A631A31F4Q57091953-2A229C56-5F3B-4539-8363-5BDD9A71B172
P2860
The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
The cholera toxin-derived CTA1 ...... mulate in the nervous tissues.
@en
type
label
The cholera toxin-derived CTA1 ...... mulate in the nervous tissues.
@en
prefLabel
The cholera toxin-derived CTA1 ...... mulate in the nervous tissues.
@en
P2093
P1476
The cholera toxin-derived CTA1 ...... mulate in the nervous tissues.
@en
P2093
Anna M Eriksson
Karin M Schön
Nils Y Lycke
P304
P356
10.4049/JIMMUNOL.173.5.3310
P407
P577
2004-09-01T00:00:00Z